Arthroplasty
Bisphosphonates in revision THA ineffective in altering pseudomembrane cytokine expression
J Arthroplasty. 2010 Sep;25(6):958-6310 patients, scheduled for revision hip arthroplasty due to aseptic osteolysis, were randomized into two groups, one received the alendronate for 8 weeks prior to surgery and another received placebo. The pseudo membrane was harvested at the time of surgery and immunohistochemistry and various cytokine expressions were tested in the two groups. In conclusion, the alendronate therapy prior to revision surgery for total hip arthroscopy was not effective in altering the pseudo-membrane cytokine expression.
Unlock the full article
Get unlimited access to OrthoEvidence with a free trial
Start TrialCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or continue reading this full article
Register Now
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
